<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04177719</url>
  </required_header>
  <id_info>
    <org_study_id>00908</org_study_id>
    <nct_id>NCT04177719</nct_id>
  </id_info>
  <brief_title>Neurobiological Effects of Oxytocin in Schizophrenia</brief_title>
  <official_title>Understanding the Neurobiological Effects of Oxytocin on Social Trust Deficits in Schizophrenia: A Multimodal Imaging - Genetics Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Mental Health and Neuro Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Mental Health and Neuro Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      22 male patients with schizophrenia and 22 male healthy volunteers will be included in the&#xD;
      study. Subjects who meet the inclusion and exclusion criteria for the study will be&#xD;
      recruited. After completion of clinical assessments and neuropsychological assessments, all&#xD;
      subjects will undergo two multi-modal imaging sessions. In one scan they will receive&#xD;
      intranasal oxytocin and in another scan will receive intranasal saline as control. The order&#xD;
      of administration of the medication will be counterbalanced and subjects will be blind to the&#xD;
      medication administered. Using the simultaneous PET-MRI scanner, PET and fMRI data will be&#xD;
      collected simultaneously. Blood will be collected for analysis of oxytocin receptor gene&#xD;
      polymorphism and its potential effect on brain activity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 8, 2019</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PET</measure>
    <time_frame>90 minues</time_frame>
    <description>changes in [18F] flumazenil specific binding</description>
  </primary_outcome>
  <primary_outcome>
    <measure>fMRI changes</measure>
    <time_frame>90 minutes</time_frame>
    <description>changes in brain functional connectivity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MRS</measure>
    <time_frame>90 minutes</time_frame>
    <description>Changes in brain chemistry measured using MRS</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-dose oxytocin or placebo will be given intranasally on separate scan days. The order of administration will be counterbalanced</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single-dose oxytocin or placebo will be given intranasally on separate scan days. The order of administration will be counterbalanced</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>oxytocin will be given intranasally. The order of administration will be counterbalanced</description>
    <arm_group_label>Oxytocin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline placebo will be given intranasally. The order of administration will be counterbalanced</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Schizophrenia group&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of schizophrenia or schizoaffective disorder&#xD;
&#xD;
          2. Males between 18 and 45 years&#xD;
&#xD;
          3. capacity to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. current comorbid axis I diagnosis and no alcohol/substance abuse/dependence in the&#xD;
             last 12 months (except nicotine)&#xD;
&#xD;
          2. Contraindication to oxytocin like hypersensitivity, vascular disease, chronic&#xD;
             nephritis, epilepsy, asthma&#xD;
&#xD;
          3. Contraindication to MRI like implants/claustrophobia&#xD;
&#xD;
          4. Past history of head injury resulting in loss of consciousness or neurosurgery&#xD;
&#xD;
          5. Concomitant severe medical conditions&#xD;
&#xD;
          6. On treatment with benzodiazepine medications for at least 8 weeks&#xD;
&#xD;
          7. Contraindication to Positron emission tomography&#xD;
&#xD;
        Healthy volunteers&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Males between 18 and 45 years&#xD;
&#xD;
          2. capacity to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Lifetime diagnosis of psychiatric illness including substance dependence&#xD;
&#xD;
          2. contraindication to oxytocin like hypersensitivity, vascular disease, chronic&#xD;
             nephritis, epilepsy, asthma&#xD;
&#xD;
          3. contraindication to MRI like implants/claustrophobia&#xD;
&#xD;
          4. past history of head injury resulting in loss of consciousness or neurosurgery&#xD;
&#xD;
          5. concomitant severe medical conditions&#xD;
&#xD;
          6. on treatment with benzodiazepine medications for at least 8 weeks&#xD;
&#xD;
          7. contraindication to Positron emission tomography&#xD;
&#xD;
          8. Family history of schizophrenia, schizoaffective or schizophreniform disorder in&#xD;
             family member&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Naren P Rao, MD</last_name>
    <phone>08026995879</phone>
    <email>narenrao@nimhans.ac.in</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Institute of Mental Health and Neurosciecnes</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560029</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naren P Rao, MD</last_name>
      <phone>08026995879</phone>
      <email>narenrao@nimhans.ac.in</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 22, 2019</study_first_submitted>
  <study_first_submitted_qc>November 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2019</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute of Mental Health and Neuro Sciences, India</investigator_affiliation>
    <investigator_full_name>Dr Naren P Rao</investigator_full_name>
    <investigator_title>Additional Professor of Psychiatry</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

